John E. Imhoff, a significant shareholder in Guided Therapeutics Inc., has made a notable move by converting a portion of his convertible promissory note into common stock. This transaction, filed on October 27, 2026, indicates a strong commitment to the company's future and may influence investor sentiment in the electromedical sector.

According to the SEC filing, Imhoff converted $115,515.07 of his outstanding convertible promissory note into 1,650,215 shares of common stock at a conversion price of $0.07 per share. The note was originally issued on September 25, 2025, and was convertible at the holder's election upon nonpayment of scheduled installments. Following this conversion, Imhoff has paid off the note in full and now holds a total of 22,902,888 shares in Guided Therapeutics.

Background

Guided Therapeutics Inc. operates within the electromedical and electrotherapeutic apparatus sector. The company is based in Peachtree Corners, Georgia, and has undergone various changes, including a name change from SpectRx Inc. in 1997. The company is listed under the SEC file number 000-22179.

What the Filing Says

The filing details that on September 30, 2026, Imhoff converted his note into shares, which included $110,000 of principal and $5,515.07 of accrued interest. The conversion also included deferred installments totaling $60,000 due from April to September 2026 and $50,000 scheduled for October 2026 through February 2027. The filing states, "Following the conversion, the note has been paid in full." This move showcases Imhoff's confidence in the company's trajectory.

Impact

This transaction may affect various stakeholders, including current shareholders and potential investors, as it reflects Imhoff's strong belief in Guided Therapeutics' future. With Imhoff now holding over 22 million shares, his actions may influence market perceptions of the company's stability and growth potential.

What's Next

The filing does not say what happens next.